Mainz Biomed NV Investor Relations Material
Latest events
H2 2024
1 Apr, 2025
H1 2024
21 Oct, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Mainz Biomed NV
Access all reports
Mainz Biomed NV is a Germany-based molecular genetics diagnostic company focused on early detection of cancer. The company develops and commercializes in-vitro diagnostic tests, including non-invasive screening tools for colorectal cancer and other conditions. It operates in European and global markets with a focus on regulated clinical validation. The company is headquartered in Mainz, Germany, and its shares are listed on the NASDAQ.
Key slides for Mainz Biomed NV
H2 2024
Mainz Biomed NV
H2 2024
Mainz Biomed NV
Latest articles
)
Novo Nordisk: Tipping the Scale of Innovation
Taking a look at the company behind Ozempic and Wegovy and diving into their history, business, and the challenges it now faces
8 Aug 2025
)
Global Doughmination: Breaking Down Domino's Pizza
Inside the rise of Domino's Pizza: how franchising, delivery control, and supply chain mastery built one of the world's most efficient food empires.
18 Jul 2025
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
Ticker symbol
MYNZ
Country
🇺🇸 United States